Skip to main content

Neal Edward Ready

Professor of Medicine
Medicine, Medical Oncology
Duke Box 3198, RM25178 Morris Bldg/ 200 Trent Dr., Durham, NC 27710
25178 Morris Bldg-200 Trent Dr., Box 3198, Durham, NC 27710

Selected Grants


DS7300-127 HAB08860

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027

Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)

Clinical TrialPrincipal Investigator · Awarded by Memgen, Inc · 2022 - 2026

BMS 050

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2026

MK-7902-009-00 LEAP-009

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2020 - 2025

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Clinical TrialPrincipal Investigator · Awarded by Merck · 2020 - 2025

DS7300-127 HAB08860

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027

Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)

Clinical TrialPrincipal Investigator · Awarded by Memgen, Inc · 2022 - 2026

BMS 050

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2026

MK-7902-009-00 LEAP-009

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2020 - 2025

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Clinical TrialPrincipal Investigator · Awarded by Merck · 2020 - 2025

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies

ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2022

A phase 1 / 2 multicenter study of BMS-986012 in subjects with relapsed/refractory small cell lung cancer.

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2022

Evaluating the Impact of PCSK9 on the Composition of the Tumor-Immune Microenvironment and Treatment Response to Immune Checkpoint Blockade in NSCLC

FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2021 - 2022

Identifying Epigenetic Biomarkers that Predict Response to Immunotherapy in Lung Cancer Patients

ResearchMentor · Awarded by Lung Cancer Initiative of North Carolina · 2020 - 2022

BMS CA 209-331-001 An Open label, Randomized Phase 3 Study of Nivolumab or Chemo

Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2015 - 2022

M16-298 (MERU)

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2020

TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by TESARO · 2019 - 2019

BMS PROTOTYPE LUNG PROGRAM - 3 DAY PROGRAMMING

ConferencePrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2019

Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer

FellowshipMentor · Awarded by Lung Cancer Initiative of North Carolina · 2015 - 2018

A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth factor receptor.

Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2018

Nivolumab with or without nab-Paclitaxel in previously treated, advanced stage, non-small cell lung cancer: a randomized Phase II study

Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2017 - 2018

Programs in Clinical Effectiveness of Cancer Pharmacogenomics

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2012

Refining and Validating Genomic Signatures in Lung Cancer

ResearchInvestigator · Awarded by National Institutes of Health · 2009 - 2010

External Relationships


  • AbbVie Pharmaceuticals
  • Adnexis (Bristol-Myers Squibb)
  • AstraZeneca
  • Daiichi Sankyo Co., Ltd
  • FLX/ RAPT Biotherapeutics
  • AbbVie Pharmaceuticals
  • Adnexis (Bristol-Myers Squibb)
  • AstraZeneca
  • Daiichi Sankyo Co., Ltd
  • FLX/ RAPT Biotherapeutics
  • Fosun Pharma
  • Genentech, Inc (Roche Holding)
  • Jazz Pharmaceuticals
  • Lilly
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Pfizer Inc.
  • Sanofi and Regeneron Pharmaceuticals

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.